Citigroup
RCKT icon

Citigroup’s Rocket Pharmaceuticals RCKT Stock Holding History

Citigroup’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,900
Closed -$400K – 5860
2025
Q1 		$400K Buy
+59,900
New +$592K ﹤0.01% 3800

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citigroup's RCKT Position: Q1 2026 in Review

Citigroup reduced its Rocket Pharmaceuticals (RCKT) stake by 2.6% in Q1 2026, selling an estimated $551K and leaving 5,107,708 shares worth $18.3M. The position accounts for 0.01% of the portfolio, ranked #1116.

Citigroup first reported a position in RCKT in Q1 2015 and has held it in 39 quarters since. The position peaked at $18.4M in Q4 2025. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Citigroup held 5,107,708 shares of Rocket Pharmaceuticals worth $18.3M as of Q1 2026.
  • Citigroup sold 138,641 Rocket Pharmaceuticals shares in Q1 2026, an estimated $551K.
  • Rocket Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #1116 holding.
  • Citigroup first reported a position in Rocket Pharmaceuticals in Q1 2015 and has held it in 39 quarters since.
  • Citigroup's Rocket Pharmaceuticals position peaked at $18.4M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.